Close Menu

NEW YORK – CareDx reported after the close of the market on Thursday that its third quarter revenues rose 60 percent year over year, thanks largely to a 68 percent increase in testing services revenues.

For the three months ended Sept. 30, the molecular diagnostics company reported total revenues of $33.8 million, up from $21.2 million during the same period a year earlier and beating the average Wall Street estimate of $33.1 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.